JP5389662B2 - 高濃度のグアニン・モノマーを含有するオリゴヌクレオチド - Google Patents

高濃度のグアニン・モノマーを含有するオリゴヌクレオチド Download PDF

Info

Publication number
JP5389662B2
JP5389662B2 JP2009541546A JP2009541546A JP5389662B2 JP 5389662 B2 JP5389662 B2 JP 5389662B2 JP 2009541546 A JP2009541546 A JP 2009541546A JP 2009541546 A JP2009541546 A JP 2009541546A JP 5389662 B2 JP5389662 B2 JP 5389662B2
Authority
JP
Japan
Prior art keywords
oligonucleotide
solvent
seq
coupling
nucleoside
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2009541546A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010512169A5 (enExample
JP2010512169A (ja
Inventor
ブライアン， スティーヴン スプロート，
Original Assignee
サイトス バイオテクノロジー アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サイトス バイオテクノロジー アーゲー filed Critical サイトス バイオテクノロジー アーゲー
Publication of JP2010512169A publication Critical patent/JP2010512169A/ja
Publication of JP2010512169A5 publication Critical patent/JP2010512169A5/ja
Application granted granted Critical
Publication of JP5389662B2 publication Critical patent/JP5389662B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2009541546A 2006-12-12 2007-12-12 高濃度のグアニン・モノマーを含有するオリゴヌクレオチド Active JP5389662B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86958806P 2006-12-12 2006-12-12
US60/869,588 2006-12-12
PCT/US2007/087183 WO2008073960A2 (en) 2006-12-12 2007-12-12 Oligonucleotides containing high concentrations of guanine monomers

Publications (3)

Publication Number Publication Date
JP2010512169A JP2010512169A (ja) 2010-04-22
JP2010512169A5 JP2010512169A5 (enExample) 2011-03-24
JP5389662B2 true JP5389662B2 (ja) 2014-01-15

Family

ID=39456527

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009541546A Active JP5389662B2 (ja) 2006-12-12 2007-12-12 高濃度のグアニン・モノマーを含有するオリゴヌクレオチド

Country Status (7)

Country Link
US (3) US8586728B2 (enExample)
EP (1) EP2125854B1 (enExample)
JP (1) JP5389662B2 (enExample)
CN (1) CN101611048B (enExample)
AU (1) AU2007333147B2 (enExample)
CA (1) CA2671873C (enExample)
WO (1) WO2008073960A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008063490B4 (de) * 2008-12-17 2023-06-15 Merck Patent Gmbh Organische Elektrolumineszenzvorrichtung und Verfahren zum Einstellen des Farbortes einer weiß emittierenden Elektrolumineszenzvorrichtung
WO2012059510A1 (en) 2010-11-02 2012-05-10 Girindus America, Inc. Back pressure control during solid-phase synthesis on polymeric supports
US10040048B1 (en) 2014-09-25 2018-08-07 Synthego Corporation Automated modular system and method for production of biopolymers
CN107428813B (zh) 2014-12-31 2021-08-03 查克美特制药公司 组合肿瘤免疫疗法
JP6891162B2 (ja) * 2015-07-08 2021-06-18 クロス バイオサイエンシズ アーゲー グアニンリッチオリゴヌクレオチド
WO2017173334A1 (en) 2016-04-01 2017-10-05 Checkmate Pharmaceuticals, Inc. Fc receptor-mediated drug delivery
US20190076814A1 (en) 2017-09-11 2019-03-14 Synthego Corporation Biopolymer synthesis system and method
WO2019080704A1 (zh) * 2017-10-25 2019-05-02 深圳华大生命科学研究院 用于核酸合成的微流控芯片
WO2019160866A2 (en) 2018-02-13 2019-08-22 Checkmate Pharmaceuticals, Inc. Compositions and methods for tumor immunotherapy
WO2019197965A1 (en) 2018-04-09 2019-10-17 Checkmate Pharmaceuticals Packaging oligonucleotides into virus-like particles
AU2019340388B2 (en) * 2018-09-11 2026-01-08 Amgen Inc. Purification methods for guanine-rich oligonucleotides
KR102899530B1 (ko) * 2018-10-30 2025-12-15 도레이 카부시키가이샤 핵산의 비특이 결합 억제제, 하이브리디제이션용 시약, 및 핵산의 하이브리디제이션 방법
CN112969527A (zh) * 2018-11-08 2021-06-15 深圳华大生命科学研究院 一种微流控芯片及其制备方法和dna合成方法
WO2021075423A1 (ja) * 2019-10-18 2021-04-22 富士フイルム和光純薬株式会社 ホスホロアミダイト活性化剤
US20230322842A1 (en) * 2020-04-14 2023-10-12 Sumitomo Chemical Company, Limited Composition containing nucleic acid oligomer
CN114425443B (zh) * 2020-10-29 2025-10-31 江苏金斯瑞生物科技有限公司 一种寡核苷酸合成催化剂
GB202114688D0 (en) 2021-10-14 2021-12-01 Exactmer Ltd Solution phase polymer synthesis

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984004749A1 (en) 1983-06-01 1984-12-06 Beckman Instruments Inc Novel preparation of nucleoside phosphoramidite intermediates
US20030050263A1 (en) 1994-07-15 2003-03-13 The University Of Iowa Research Foundation Methods and products for treating HIV infection
JP4111403B2 (ja) 1996-10-11 2008-07-02 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア 免疫刺激ポリヌクレオチド／免疫調節分子複合体
AU7350798A (en) 1997-04-29 1998-11-24 Universiteit Utrecht Corona virus-like particles as tools for vaccination and therapy
CA2288129A1 (en) 1997-05-01 1998-11-12 Chiron Corporation Use of virus-like particles as adjuvants
US6171591B1 (en) 1997-12-08 2001-01-09 Pentamer Pharmaceuticals, Inc. Recombinant nodavirus compositions and methods
US6541438B1 (en) 1998-05-01 2003-04-01 The Procter & Gamble Company Laundry detergent and/or fabric care compositions comprising a modified cellulase
ATE314095T1 (de) 1998-10-21 2006-01-15 Us Health Virusähnliche partikel zur induktion von autoantikörpern
AU768807B2 (en) 1998-11-30 2004-01-08 Cytos Biotechnology Ag Ordered molecular presentation of antigens, method of preparation and use
EP1165773A4 (en) 1999-02-02 2005-01-05 Biocache Pharmaceuticals Inc IMPROVED PLATFORM FOR PRESENTING ANTIGENS
EP2286792A1 (en) 1999-02-26 2011-02-23 Novartis Vaccines and Diagnostics, Inc. Microemulsions with an adsorbent surface, comprising a microdroplet emulsion
KR100863630B1 (ko) 1999-09-25 2008-10-15 유니버시티 오브 아이오와 리써치 파운데이션 면역자극성 핵산
US6949520B1 (en) 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
IL148844A0 (en) 1999-09-27 2002-09-12 Coley Pharm Group Inc Methods related to immunostimulatory nucleic acid-induced interferon
ATE454901T1 (de) 1999-10-13 2010-01-15 Novartis Vaccines & Diagnostic Verfahren zur erhaltung zellimmuneantworten gegen proteinen
DE60018601T4 (de) 1999-11-24 2008-05-21 Chiron Corp., Emeryville HBV/HCV Virus-ähnliche Partikel
AT409085B (de) 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
EP1261366A4 (en) 2000-02-24 2003-06-18 Univ Leland Stanford Junior ADJUVANT TREATMENT BY IN VIVO ACTIVATION OF DENDRITIC CELLS
AU2002248185A1 (en) 2000-12-14 2002-07-16 Coley Pharmaceutical Group, Inc. Inhibition of angiogenesis by nucleic acids
US20030050268A1 (en) 2001-03-29 2003-03-13 Krieg Arthur M. Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
AU2002347404A1 (en) 2001-09-14 2003-04-01 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
DE60234375D1 (de) 2001-09-14 2009-12-24 Cytos Biotechnology Ag VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG
US7524950B2 (en) * 2001-10-31 2009-04-28 Agilent Technologies, Inc. Uses of cationic salts for polynucleotide synthesis
CA2488856A1 (en) 2002-06-20 2003-12-31 Cytos Biotechnology Ag Packaged virus-like particles for use as adjuvants: method of preparation and use
US7537767B2 (en) 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
US20060210588A1 (en) 2003-03-26 2006-09-21 Cytos Biotechnology Ag Hiv-peptide-carrier-conjugates
EP1605973B1 (en) 2003-03-26 2012-09-26 Cytos Biotechnology AG Packaging of immunostimulatory oligonucleotides into virus-like particles: methods of preparation and uses
US20060251623A1 (en) 2003-07-10 2006-11-09 Caytos Biotechnology Ag Packaged virus-like particles
CA2544240A1 (en) * 2003-07-22 2005-02-17 Cytos Biotechnology Ag Cpg-packaged liposomes
JP4628686B2 (ja) 2004-02-25 2011-02-09 独立行政法人科学技術振興機構 ホスホロアミダイトを含む３’末端ヌクレオシドユニット
EP1789460B1 (en) * 2004-09-02 2013-01-09 Isis Pharmaceuticals, Inc. Polymeric beads for oligonucleotide synthesis
AU2005286475A1 (en) 2004-09-21 2006-03-30 Cytos Biotechnology Ag Virus-like particles comprising a fusion protein of the coat protein of AP205 and an antigenic polypeptide
JP5484732B2 (ja) 2005-12-14 2014-05-07 サイトス バイオテクノロジー アーゲー 過敏症の治療のための免疫賦活性核酸パッケージ粒子

Also Published As

Publication number Publication date
US8586728B2 (en) 2013-11-19
EP2125854A2 (en) 2009-12-02
WO2008073960A2 (en) 2008-06-19
CA2671873C (en) 2018-10-09
US20080139797A1 (en) 2008-06-12
AU2007333147A1 (en) 2008-06-19
AU2007333147B2 (en) 2013-12-19
US20140200338A1 (en) 2014-07-17
JP2010512169A (ja) 2010-04-22
CN101611048A (zh) 2009-12-23
US9914746B2 (en) 2018-03-13
CA2671873A1 (en) 2008-06-19
US20160145293A1 (en) 2016-05-26
EP2125854B1 (en) 2016-10-26
WO2008073960A3 (en) 2008-08-07
CN101611048B (zh) 2012-11-07

Similar Documents

Publication Publication Date Title
JP5389662B2 (ja) 高濃度のグアニン・モノマーを含有するオリゴヌクレオチド
JP7377228B2 (ja) グアニンリッチオリゴヌクレオチド
JP2010248084A (ja) 新規洗浄溶媒を用いるオリゴヌクレオチド合成法
CN109661233A (zh) 缀合低聚化合物的方法
CN102076703B (zh) 用于制造寡核苷酸的方法
KR20230145318A (ko) 올리고뉴클레오타이드의 탈트리틸화 방법
EP1105404A1 (en) Purification of oligomers using dual-end selection
KR102709587B1 (ko) 이메텔스타트를 제조하기 위한 향상된 공정
CA2424716A1 (en) Process for producing multiple oligonucleotides on a solid support
US20030195351A1 (en) Methods for the integrated synthesis and purification of oligonucleotides
AU2013204442A1 (en) Oligonucleotides Containing High Concentrations of Guanine Monomers
Menéndez-Méndez et al. Manual and automated synthesis of modified oligonucleotides on core–shell solid supports
ES2741025T3 (es) Oligonucleótidos ricos en guanina
JP2000342265A (ja) オリゴヌクレオチド類の精製方法
Xu et al. Site-specific introduction of functional groups onto bases in synthetic oligonucleotides for biological applications
HK40031465B (en) Improved process for preparing imetelstat
HK40031465A (en) Improved process for preparing imetelstat

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20101210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20101213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130219

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130517

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130521

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130524

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130528

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130819

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130917

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131009

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 5389662

Country of ref document: JP

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250